VivoSeq
Oncology

B Acute Lymphoblastic Leukemia With T(9;22)(q34.1;q11.2); BCR-ABL1

15

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 is an emerging landscape with 15 programs across 9 companies. The most active players are Teva, Alnylam Pharmaceuticals, Amgen. 11 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3Amgen logo

Amgen

1 program

Phase 3K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3E

Eastern Cooperative Oncology Group

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

11 of 15 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody213%Antibody–drug conjugate17%Protein / enzyme17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT04530565·348 enrolled
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT01371630·276 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)